Abstract:Although prognostic factors of nasopharyngeal carcinoma (NPC) have been studied extensively, most of data of these studies are from an endemic area; databases from nonendemic areas are rare. The purpose of this study is to investigate the long-term outcome and prognostic factors analysis for NPC patients receiving 3-dimensional conformal radiation therapy/intensity modulated radiation therapy (3DCRT/IMRT) in a nonendemic area of China. Between January 2004 and December 2011, a total of 393 nonmetastatic and histologically proven NPC patients were identified. All patients received 3DCRT or IMRT. The prognostic factors we analyzed included age, T stage, N stage, lymph node diameter, tumor volume, WHO histology types, and cranial nerve-related symptoms. All patients were staged according to the 7th edition of the American Joint Committee on Cancer (AJCC) system. Factors found to be associated with the endpoints by univariate analyses and then entered into multivariate Cox proportional hazards regression analysis. Continuous variables were divided into 2 subgroups at cut-off values identified by receiver operating characteristic curves and then analyzed. The median follow-up time was 58.3 months (range: 4-130 months). For all patients, the 5-year overall survival (OS), progression-free survival (PFS), locoregional-free survival (LRFS), and distant metastatic-free survival (DMFS) were 71.2%, 60.6%, 84.2%, and 71.6%, respectively. Univariate analyses showed that the risk factors for OS, PFS, and DMFS included T stage (T1-2 vs T3-4), N stage (N0-1 vs N2-3), lymph node diameter (≥3 cm vs <3 cm), cranial nerve symptoms (with vs without), tumor volume (≤40 mL vs >40 mL) and WHO histology types (WHO II vs WHO III). Multivariate analysis indicated that N stage, WHO pathologic types, and tumor volume were 3 independent prognostic factors for OS, PFS, and DMFS. We identified 3 subgroups according to the number of independent risk factors: group 1 (patients with no risk factor), group 2 (patients with only 1 risk factor) and group 3 (patients with more than 2 risk factors). The 5-year OS, PFS, and DMFS for group 1 versus group 2 versus group 3 were 91.5% versus 75.2% versus 49.3%, 82.6% versus 63.5% versus 39.8% and 89.4% versus 77.9% versus 49.4%, respectively (all P<.05) in all patients. N stage, WHO histology types, and tumor volume are independent prognostic indicators for survival outcomes in NPC patients from a nonendemic area of China.

A Comprehensive Analysis of Treatment Management and Survival Outcomes in Nasopharyngeal Carcinoma

Retrospective Analysis of 234 Nasopharyngeal Carcinoma Patients with Distant Metastasis at Initial Diagnosis: Therapeutic Approaches and Prognostic Factors

Factors Associated with Overall Survival in 1706 Patients with Nasopharyngeal Carcinoma: Significance of Intensive Neoadjuvant Chemotherapy and Radiation Break.

The Characteristics and Survival Outcomes in Patients Aged 70 Years and Older with Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era

The role of chemotherapy in the treatment of stage II nasopharyngeal carcinoma: Retrospective analysis of the national cancer database

Conditional Survival of Nasopharyngeal Carcinoma in the Era of Intensive Modulated Radiation Therapy

A National Study of Survival Trends and Conditional Survival in Nasopharyngeal Carcinoma: Analysis of the National Population-Based Surveillance Epidemiology and End Results Registry

Long-term Outcome and Prognostic Factor Analysis for Nasopharyngeal Carcinoma Patients Receiving 3DCRT/IMRT in Nonendemic Area of China

Patterns of Failure and Survival Trends Of 720 Patients with Stage I Nasopharyngeal Carcinoma Diagnosed from 1990-2012: A Large-scale Retrospective Cohort Study.

Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Treatment Outcomes of a Prospective, Multicentric Clinical Study

Elderly nasopharyngeal carcinoma patients (aged ≥70 years): Survival and treatment strategies

Survival benefit of radiotherapy for metastatic nasopharyngeal carcinoma: a retrospective analysis based on SEER database

Neoadjuvant Chemotherapy And Prognostic Subgroups Defined By Survival Benefit In Patients With Locoregionally Advanced Nasopharyngeal Carcinoma.

Long-term Survivals, Toxicities and the Role of Chemotherapy in Early-Stage Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiation Therapy: A Retrospective Study with 15-Year Follow-up

Long-term outcomes of metastasis-directed stereotactic body radiation therapy in metastatic nasopharyngeal carcinoma

Is Nasopharyngeal Carcinoma in Young Patients A Distinct Clinical Entity? A Single-Institution Case Matched Analysis in the Era of Intensity-Modulated Radiotherapy

Nasopharyngeal Carcinoma: Clinical Achievements and Considerations Among Treatment Options

Impact of Radiotherapy Combined with Chemotherapy on Long-Term Outcomes of Patients with Recurrent Nasopharyngeal Carcinoma

Long-term Outcomes of Induction Chemotherapy Followed by Intensity-Modulated Radiotherapy and Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients with N3 Disease

Efficacy of Chemoradiotherapy in Survival of Stage Ⅳ Nasopharyngeal Carcinoma and Establishment of a Prognostic Model.

Systemic Chemotherapy and Sequential Locoregional Radiotherapy in Initially Metastatic Nasopharyngeal Carcinoma: Retrospective Analysis with 821 Cases